Of course, this case is about more than just two genes. Here's how renowned human genetics professor Stephen Warren (also a plaintiff) contextualizes the Myriad case: "[W]ith the completion of the human genome and improvements in DNA sequencing methodologies, full genome sequencing of individual patients is soon to be affordable," he writes. However, "because of exclusive gene testing patents [such as the one held by Myriad], no single laboratory in the United States could offer full genome sequencing for clinical purposes. Is this fair to the taxpayers — potential patients — who footed the $3 billion cost of the genome project?"
Myriad claims its patents are on synthetic DNA molecules that "are different from what is found in nature or the human body." The Supreme Court is expected to issue its decision in June.
: This Just In
, Supreme Court